Killing time for cancer cells

被引：73

作者：

Klein, S

McCormick, F

Levitzki, A

机构：

[1] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA

[2] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signalling, IL-91904 Jerusalem, Israel

来源：

NATURE REVIEWS CANCER | 2005年 / 5卷 / 07期

关键词：

D O I：

10.1038/nrc1651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As the signalling pathways that control cellular proliferation and death are unravelled, a range of targets have emerged as candidates for molecular cancer therapy. For their survival, cancer cells depend on a few highly activated signalling pathways; inhibition of these pathways has a strong apoptotic effect and can lead to tumour regression. But drugs that exploit this weakness, such as imatinib, have not cured patients: withdrawal of the drug leads to disease recurrence, and sustained treatment leads to the emergence of drug- resistant clones. Can cancer be cured, or will it have to be controlled as a chronic disease?

引用

收藏

页码：573 / 580

页数：9

相关论文

共 67 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[3] Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors [J].

Barnett, SF ;

Defeo-Jones, D ;

Fu, S ;

Hancock, PJ ;

Haskell, KM ;

Jones, RE ;

Kahana, JA ;

Kral, AM ;

Leander, K ;

Lee, LL ;

Malinowski, J ;

McAvoy, EM ;

Nahas, DD ;

Robinson, RG ;

Huber, HE .

BIOCHEMICAL JOURNAL, 2005, 385 :399-408

[4] ROS, stress-activated kinases and stress signaling in cancer [J].

Benhar, M ;

Engelberg, D ;

Levitzki, A .

EMBO REPORTS, 2002, 3 (05) :420-425

[5] Opinion - The role of apoptosis in cancer development and treatment response [J].

Brown, JM ;

Attardi, LD .

NATURE REVIEWS CANCER, 2005, 5 (03) :231-237

[6]

Buchdunger E, 1996, CANCER RES, V56, P100

[7]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[8] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS [J].

BUCHDUNGER, E ;

ZIMMERMANN, J ;

METT, H ;

MEYER, T ;

MULLER, M ;

REGENASS, U ;

LYDON, NB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2558-2562

[9] To the editor: Discontinuation of imatinib therapy after achieving a molecular response [J].

Cortes, J ;

O'Brien, S ;

Kantarjian, H .

BLOOD, 2004, 104 (07) :2204-2205

[10] Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group [J].

Debiec-Rychter, M ;

Dumez, H ;

Judson, I ;

Wasag, B ;

Verweij, J ;

Brown, M ;

Dimitrijevic, S ;

Sciot, R ;

Stul, M ;

Vranck, H ;

Scurr, M ;

Hagemeijer, A ;

Van Glabbeke, M ;

van Oosterom, AT .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :689-695

← 1 2 3 4 5 6 7 →